AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD Patients
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT04168216
- Locations
- 🇬🇧
Research Site, Oxford, Oxfordshire, United Kingdom
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Phase 4
Completed
- Conditions
- Severe Eosinophilic AsthmaAsthma
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 170
- Registration Number
- NCT04159519
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
Phase 3
Active, not recruiting
- Conditions
- Eosinophilic Granulomatous Vasculitis
- Interventions
- Biological: Placebo to MepolizumabBiological: Placebo to Benralizumab
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT04157348
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Phase 3
Active, not recruiting
- Conditions
- Nasal Polyposis
- Interventions
- Biological: Matched placeboBiological: Benralizumab 30 mg
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT04157335
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia
Phase 1
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: AZD8233 subcutaneous injectionDrug: Placebo
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT04155645
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
Phase 1
Completed
- Conditions
- Non-alcoholic SteatohepatitisMetabolic Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT04142424
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Completed
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT04126499
- Locations
- 🇪🇸
BIG PAC, Madrid, Spain
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
Terminated
- Conditions
- Hairy Cell Leukemia
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2
- Registration Number
- NCT04125290
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Pueblo, Colorado, United States
🇺🇸Research Site, Bridgeton, Missouri, United States
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04121910
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04118842
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath